Anthera Pharmaceuticals Inc (ANTH) Short Interest Update

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was the target of a large growth in short interest in April. As of April 28th, there was short interest totalling 10,669,429 shares, a growth of 13.9% from the April 13th total of 9,365,054 shares. Based on an average daily volume of 1,747,316 shares, the short-interest ratio is currently 6.1 days.

A number of equities analysts have weighed in on ANTH shares. Zacks Investment Research lowered Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 8th. Jefferies Group LLC decreased their target price on Anthera Pharmaceuticals from $8.00 to $6.40 and set a “hold” rating on the stock in a research note on Monday, March 6th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $10.21.

Several institutional investors have recently made changes to their positions in ANTH. Sabby Management LLC increased its position in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Anthera Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 2,691,639 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 886,910 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. Abingworth LLP increased its position in shares of Anthera Pharmaceuticals by 16.9% in the third quarter. Abingworth LLP now owns 512,036 shares of the biopharmaceutical company’s stock valued at $1,531,000 after buying an additional 74,042 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Anthera Pharmaceuticals by 16.2% in the first quarter. Geode Capital Management LLC now owns 355,172 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 49,391 shares during the last quarter. Institutional investors and hedge funds own 50.87% of the company’s stock.

Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 1.63 on Friday. The company’s market capitalization is $16.42 million. Anthera Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $4.00. The firm has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.11.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.47) by $0.56. Analysts anticipate that Anthera Pharmaceuticals will post ($7.79) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/05/21/anthera-pharmaceuticals-inc-anth-short-interest-update.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

12 Month Chart for NASDAQ:ANTH

Receive News & Ratings for Anthera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply